<DOC>
	<DOCNO>NCT00216125</DOCNO>
	<brief_summary>In previous phase II study , patient pathological stage IIIb ( without pleural effusion ) NSCLC treat concurrent cisplatin etoposide plus thoracic radiotherapy follow 3 cycle consolidation therapy docetaxel . Docetaxel select base upon survival benefit patient recurrent NSCLC . This trial evaluate role consolidation therapy docetaxel patient unresectable stage III disease . The purpose trial evaluate survival toxicity regimens employ .</brief_summary>
	<brief_title>Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel Advanced Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . - Cisplatin 50 mg/m2 d1 , 8 , 29 , 36 - Etoposide 50 mg/m2/day d1-5 , 29-33 - Radiation 5940 cGy ( 180 cGy/day ) Patients CR , PR , SD Randomized either : Docetaxel75 mg/m2 q3wk X 3 cycle Observation Only Performance Status : ECOG 0 1 Life Expectancy : Not specify Hematopoietic : - ANC &gt; 1,500/mm3 - Platelet count &gt; 100,000/mm3 - Hemoglobin &gt; 8 g/dl . PRBC transfusion allow increase hemoglobin &gt; 8 g/dl Hepatic : - Serum bilirubin &lt; institutional upper limit normal ( ULN ) - AST &lt; 2.5 X upper limit normal alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 X ULN AST &lt; ULN Renal : - Serum creatinine &lt; 2 mg/dl calculate creatinine clearance &gt; 50 cc/min Cardiovascular : - No clinically significant history cardiac disease , ( i.e . uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within past year , cardiac ventricular arrhythmia require medication ) . Pulmonary : - Pre-registration FEV1 &gt; 1 liter spirometry within 42 day prior study treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>Histologic cytologic evidence NSCLCUnresectable Stage IIIA ( N2 ) OR Stage IIIB NSCLC . Unresectable Stage IIIA define follow criterion : N2 mediastinal lymph node must multiple and/or bulky CT scan opinion treat investigator , patient candidate surgical resection N2 disease must document biopsy , FDGPET scan imaging , CT nod &gt; 2 cm CT scan Stage IIIb patient must N3 T4 status . N3 status must document one follow criterion : Contralateral ( primary tumor ) mediastinal lymph node , supraclavicular scalene lymph node proven biopsy , FDGPET scan imaging , CT nod &gt; 2 cm CT scan . Patients positive supraclavicular scalene lymph node must disease extend cervical region . All patient must measurable evaluable disease document CT , MRI , Xray physical exam within 28 day prior study treatment . Negative pregnancy test Eligibility Consolidation Therapy Following completion induction chemoradiotherapy patient without local progression disease distant metastasis randomize receive consolidation therapy docetaxel observation . Patients stratify randomize base stage IIIa v IIIb disease baseline , CR vs. nonCR follow induction chemoradiation , ECOG PS 0 1 vs. 2 . Patients must complete chemoradiotherapy per protocol least 4 week 8 week must elapse last day induction therapy ( last day radiation ) eligible randomization consolidation docetaxel observation . Patients must undergo restaging test accord study calendar determine evidence disease progression eligible randomization consolidation docetaxel observation . Patients must ANC &gt; 1,500/mm3 , platelet count &gt; 100,000/ mm3 , hemoglobin &gt; 8 g/dl obtain within 14 day prior registration randomization consolidation docetaxel observation . Patients must adequate hepatic function define serum bilirubin &lt; institutional upper limit normal ( ULN ) AST and/or ALT &lt; 2.5 X upper limit normal alkaline phosphatase &lt; ULN , alkaline phosphatase may 4 X ULN transaminases &lt; ULN within 14 day prior registration randomization consolidation docetaxel observation . No prior chemotherapy radiotherapy lung cancer . No unintended weight loss &gt; 5 % body weight precede 3 month prior study treatment eligible trial . No symptomatic peripheral neuropathy prior entry onto study . Peripheral neuropathy must &lt; Grade 1 eligible . No prior malignancy except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 5 year . No history allergic reaction drug utilize vehicle polysorbate 80 ( docetaxel ) polysorbate 80 + polyethylene glycol ( etoposide ) . If patient hearing loss prestudy , performance audiogram recommend ( mandatory ) document baseline hearing status event possible hearing loss due cisplatin administration . No current breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
</DOC>